fda warning letters compounded semaglutide telehealth 2025 issued 25 to companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA Warns 30 Telehealth Companies

As the systematic review noted: No clinical safety data were found. When the FDA says insufficient evidence, they mean itwe literally do not have the data to know whether chronic BPC-157 use causes problems that emerge years down the road

The Internet Sale and Discounting of XYMOGEN formulas are strictly prohibited

This article is prepared for informational purposes only and does not constitute investment advice or a recommendation to execute any trading operations

Because tirzepatide targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, it offers a dual-action approach that can be more effective for those who are less sensitive to GLP-1 alone